These factors collectively contribute to the resistance of GBM to PD-1 blockade and may help explain why even spatially targeted transcriptomic profiling reveals no detectable treatment effects in the tumor or macrophage compartments. The gene discussed is PDCD1; the disease is glioblastoma.